Cixutumumab (IMC-A12) is a human monoclonal antibody targeting the insulin-like growth factor 1 receptor (IGF-1R) with high affinity. It effectively inhibits ligand-dependent activation of the receptor and subsequent downstream signaling pathways. Additionally, Cixutumumab facilitates the internalization and degradation of IGF-1R, contributing to its inhibitory effects. This antibody demonstrates broad-spectrum antitumor activity, making it suitable for research in various cancer types including lung cancer, leukemia, non-small cell lung cancer, and prostate cancer. Cixutumumab is an essential tool for studies exploring the role of the IGF-1R pathway in cancer pathogenesis and therapy.
Cixutumumab (IMC-A12) is a human monoclonal antibody targeting the insulin-like growth factor 1 receptor (IGF-1R) with high affinity. It effectively inhibits ligand-dependent activation of the receptor and subsequent downstream signaling pathways. Additionally, Cixutumumab facilitates the internalization and degradation of IGF-1R, contributing to its inhibitory effects. This antibody demonstrates broad-spectrum antitumor activity, making it suitable for research in various cancer types including lung cancer, leukemia, non-small cell lung cancer, and prostate cancer. Cixutumumab is an essential tool for studies exploring the role of the IGF-1R pathway in cancer pathogenesis and therapy.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
